A novel liposomal formulation of FTY720 (Fingolimod) for promising enhanced targeted delivery

被引：32

作者：

Mao, Yicheng ^{[1
,2
]}

Wang, Jiang ^{[2
]}

Zhao, Yuan ^{[2
]}

Wu, Yun ^{[1
,3
]}

Kwak, Kwang Joo ^{[1
,3
]}

Chen, Ching-Shih ^{[4
]}

Byrd, John C. ^{[5
]}

Lee, Robert J. ^{[1
,2
]}

Phelps, Mitch A. ^{[2
]}

Lee, L. James ^{[1
,3
]}

Muthusamy, Natarajan ^{[5
]}

机构：

[1] Ohio State Univ, Ctr Affordable Nanoengn Polymer Biomed Devices CA, Columbus, OH 43210 USA

[2] Ohio State Univ, Coll Pharm, Div Pharmaceut, Columbus, OH 43210 USA

[3] Ohio State Univ, William G Lowrie Dept Chem & Biomol Engn, Columbus, OH 43210 USA

[4] Ohio State Univ, Div Med Chem & Pharmacognosy, Columbus, OH 43210 USA

[5] Ohio State Univ, Dept Internal Med, Div Hematol & Oncol, Columbus, OH 43210 USA

来源：

NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE | 2014年 / 10卷 / 02期

关键词：

FTY720; Liposome; Leukemia; Drug delivery; CD37; Nanotechnology; CHRONIC LYMPHOCYTIC-LEUKEMIA; THERAPEUTIC-EFFICACY; PRECLINICAL ACTIVITY; TRANSPLANT PATIENTS; IMMUNOLIPOSOMES; APOPTOSIS; PHARMACOKINETICS; ACTIVATION; MECHANISM; DRUG;

D O I：

10.1016/j.nano.2013.08.001

中图分类号：

TB3 [工程材料学];

学科分类号：

0805 ; 080502 ;

摘要：

We describe here the development and characterization of the physicochemical and pharmacokinetic properties of a novel liposomal formulation for FTY720 delivery, LP-FTY720. The mean diameter of LP-FTY720 was similar to 157 nm, and the FTY720 entrapment efficiency was similar to 85%. The liposomal formulation protected FTY720 from degradation in aqueous buffer and showed toxicity in CLL patient B cells comparable to that of free FTY720. Following intravenous injection in ICR mice, LP-FTY720 had an increased elimination phase half-life (similar to 28 vs. similar to 19 hr) and decreased clearance (235 vs. 778 mL/h/kg) compared to the free drug. Antibodies against CD19, CD20 and CD37 were incorporated into LP-FTY720, which provided targeted delivery to CLL patient B cells and thus achieved higher killing efficacy. The novel liposomal carrier of FTY720 demonstrated improved pharmacokinetic properties, comparable activity, and a potential platform for targeted delivery to CLL by overcoming the limited application of free FTY720 to B malignancy treatment. Published by Elsevier Inc.

引用

页码：393 / 400

页数：8

共 43 条

[1] FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death [J].

Alinari, Lapo ;

Mahoney, Emilia ;

Patton, John ;

Zhang, Xiaoli ;

Lenguyen Huynh ;

Earl, Christian T. ;

Mani, Rajeswaran ;

Mao, Yicheng ;

Yu, Bo ;

Quinion, Carl ;

Towns, William H. ;

Chen, Ching-Shih ;

Goldenberg, David M. ;

Blum, Kristie A. ;

Byrd, John C. ;

Muthusamy, Natarajan ;

Praetorius-Ibba, Mette ;

Baiocchi, Robert A. .

BLOOD, 2011, 118 (26) :6893-6903

[2] CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody [J].

Awan, Farrukh T. ;

Lapalombella, Rosa ;

Trotta, Rossana ;

Butchar, Jonathan P. ;

Yu, Bo ;

Benson, Don M., Jr. ;

Roda, Julie M. ;

Cheney, Carolyn ;

Mo, Xiaokui ;

Lehman, Amy ;

Jones, Jeffrey ;

Flynn, Joseph ;

Jarjoura, David ;

Desjarlais, John R. ;

Tridandapani, Susheela ;

Caligiuri, Michael A. ;

Muthusamy, Natarajan ;

Byrd, John C. .

BLOOD, 2010, 115 (06) :1204-1213

[3] Immunoliposomes - A promising approach to targeting cancer therapy [J].

Bendas, G .

BIODRUGS, 2001, 15 (04) :215-224

[4] Renal transplantation: Basic concepts and evolution of therapy [J].

Braun, WE .

JOURNAL OF CLINICAL APHERESIS, 2003, 18 (03) :141-152

[5] Sphingosine 1-phosphate receptors in health and disease: Mechanistic insights from gene deletion studies and reverse pharmacology [J].

Brinkmann, Volker .

PHARMACOLOGY & THERAPEUTICS, 2007, 115 (01) :84-105

[6] Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis [J].

Brinkmann, Volker ;

Billich, Andreas ;

Baumruker, Thomas ;

Heining, Peter ;

Schmouder, Robert ;

Francis, Gordon ;

Aradhye, Shreeram ;

Burtin, Pascale .

NATURE REVIEWS DRUG DISCOVERY, 2010, 9 (11) :883-897

[7] Liposomes modified with polycation used for gene delivery:: Preparation, characterization and transfection in vitro [J].

Chen, Jin-Liang ;

Wang, Hua ;

Gao, Jian-Qing ;

Chen, Hai-Liang ;

Liang, Wen-Quan .

INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2007, 343 (1-2) :255-261

[8] FTY720 ameliorates Th1-mediated colitis in mice by directly affecting the functional activity of CD4+CD25+ regulatory T cells [J].

Daniel, Carolin ;

Sartory, Nico ;

Zahn, Nadine ;

Geisslinger, Gerd ;

Radeke, Heinfried H. ;

Stein, Juergen M. .

JOURNAL OF IMMUNOLOGY, 2007, 178 (04) :2458-2468

[9] Clinical Pharmacokinetics of Fingolimod [J].

David, Olivier J. ;

Kovarik, John M. ;

Schmouder, Robert L. .

CLINICAL PHARMACOKINETICS, 2012, 51 (01) :15-28

[10] Nanoparticle therapeutics: an emerging treatment modality for cancer [J].

Davis, Mark E. ;

Chen, Zhuo ;

Shin, Dong M. .

NATURE REVIEWS DRUG DISCOVERY, 2008, 7 (09) :771-782

← 1 2 3 4 5 →